Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Steele, Katherine T ^a,b   Steenhoff, Andrew P ^b,c,d   Newcomb, Craig W ^a   Rantleru, Tumelo ^b   Nthobatsang, Rudo ^b   Lesetedi, Gloria ^b   Bellamy, Scarlett L ^a   Nachega, Jean B ^e   Gross, Robert ^a,b   Bisson, Gregory P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOTSWANA UPENN PARTNERSHIP   (Botswana)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ISONIAZID; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADVERSE OUTCOME; AGED; ANTIBIOTIC THERAPY; ARTICLE; BOTSWANA; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; VIRUS LOAD; DISEASE COURSE; MIDDLE AGED; PATHOPHYSIOLOGY; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTI-HIV AGENTS; BOTSWANA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 79958830270     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020010     Document Type: Article

References (42)

1. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22: 1897-1908.
2. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, et al. (2008) Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 24: 555-560.
3. Rosen S, Fox MP, Gill CJ, (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
4. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. (2006) Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296: 679-690.
5. Park WB, Choe PG, Kim SH, Jo JH, Bang JH, et al. (2007) One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients. J Intern Med 261: 268-75.
6. Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, et al. (2008) Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther 5: 23.
7. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, et al. (2006) Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20: 1-7.
8. Murdoch DM, Venter WD, Feldman C, Van Rie A, (2008) Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 22: 601-610.
9. Ssali F, Stohr W, Munderi P, Reid A, Walker AS, et al. (2006) Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 11: 741-749.
10. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, et al. (2006) HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretrovial therapy: a collaborative analysis. Lancet 368: 451-458.
11. Chene G, Sterne JA, May M, Costagliola D, Ledgerber B, et al. (2003) Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362: 679-686.
12. McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, et al. (2011) Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis 52: 493-506.
13. Bisson GP, Rowh A, Weinstein R, Gaolathe T, Frank I, et al. (2008) Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr 49: 107-110.
14. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
15. Muyingo SK, Walker AS, Reid A, Munderi P, Gibb DM, et al. (2008) Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 48: 468-475.
16. Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, et al. (2008) Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther 13: 697-703.
17. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78-84.
18. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, et al. (2009) Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 51: 65-71.
19. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, et al. (2008) Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One 3: e1725.
20. Wester CW, Bussmann H, Avalos A, Ndwapi N, Gaolathe T, et al. (2005) Establishment of a public antiretroviral treatment clinic for adults in urban Botswana: lessons learned. Clin Infect Dis 40: 1041-1044.
21. Brinkhof MW, Pujades-Rodriguez M, Egger M, (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 4: e5790.
22. World Health Organization (2005) Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS Case Definitions for Surveillance: African Region Geneva World Health Organization Available at: http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf, accessed March 15, 2011.
23. Karcher H, Omondi A, Odera J, Kunz A, Harms G, (2007) Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 12: 687-694.
24. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, et al. (2002) The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 16: 1363-1370.
25. Rockhill B, Newman B, Weinberg C, (1998) Use and misuse of population attributable fractions. Am J Public Health 88: 15-19.
26. Rothman KJ, Greenland S, Lash TL, (2008) Modern epidemiology Philadelphia Wolters Kluwer Health/Lippincott Williams & Wilkins pp. x, 758.
27. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
28. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 Revision Geneva World Health Organization Available at: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf, accessed March 20, 2011.
29. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, et al. (2002) Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16: 1051-1058.
30. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
31. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, et al. (2006) Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20: 2355-2360.
32. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, et al. (2010) Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 24: 1323-1328.
33. Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, et al. (2009) Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS 23: 707-715.
34. Haddow LJ, Easterbrook PJ, Mosam A, Khanyile NG, Parboosing R, et al. (2009) Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 49: 1424-1432.
35. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, et al. (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 8: 516-523.
36. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, et al. (2009) Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 49: 965-972.
37. Hester EK, Peacock JE Jr, (1998) Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection. AIDS 12: 439-440.
38. Leng K, Lonsdorf A, Hartmann M, (2008) Fatal outcome of nevirapine-associated toxic epidermal necrolysis. Int J STD AIDS 19: 642-643.
39. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, et al. (2003) Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 17 (Suppl 3): S5-15.
40. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, et al. (2007) Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 46: 318-322.
41. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM, (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10: 155-166.
42. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, et al. (2007) Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46: 125-133.